Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pure cannabidiol versus cannabidiol plus tetrahydrocannabinol in children with autism spectrum disorder
MOH_2018-11-05_004735Phase 2Not yet recruiting
- Sponsor
- ד"ר עדי ארן
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cannabidiol and dronabinol in Autism Spectrum Disorder (ASD) (2 arms), sponsored by ד"ר עדי ארן. Primary endpoint: Safety, tolerability, and efficacy non-inferiority of purified cannabidiol versus purified cannabidiol plus tetrahydrocannabinol. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
cannabidioldronabinol
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on MOH_2018-11-05_004735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-11-05_004735.